Engineered Gut Bacteria Slash Ammonia 10-Fold and Outperform Standard Drug
Synthetic biology meets the microbiome: designer probiotics restore gut-liver-brain balance better than rifaximin in preclinical models.
Summary
Researchers at the National University of Singapore engineered two strains of the common gut bacterium Lactobacillus plantarum to correct the metabolic imbalances that drive hepatic encephalopathy, a serious brain disorder caused by liver dysfunction. One strain captures excess ammonia and converts it into beneficial branched-chain amino acids; the other reduces ammonia production by redirecting glutamine metabolism. In animal models, these engineered bacteria cut systemic ammonia levels by up to ten times, restored amino acid balance, and reversed anxiety and cognitive impairment. Remarkably, they outperformed rifaximin, the current standard-of-care drug, while also preserving the diversity of the gut microbiome. The study positions programmable commensal bacteria as a flexible, next-generation platform for treating complex metabolic and neurological disorders linked to the gut-liver-brain axis.
Detailed Summary
The gut-liver-brain axis is a critical communication highway governing both metabolic and neurological health. When this axis breaks down — as it does in hepatic encephalopathy (HE) — toxic ammonia accumulates in the bloodstream, amino acid levels become severely imbalanced, and patients suffer debilitating cognitive and psychiatric symptoms. Current treatments like rifaximin offer only partial relief and can disrupt the gut microbiome. A new study published in Cell proposes a radically different approach: reprogramming the bacteria already living in the gut to fix the problem from within.
Researchers engineered two distinct strains of Lactobacillus plantarum WCFS1, a well-characterized commensal bacterium. The first strain was designed to capture excess ammonia and channel it directly into the biosynthesis of branched-chain amino acids (BCAAs), which are typically depleted in HE patients. The second strain was engineered to enhance L-glutamine utilization, thereby suppressing one of the main biochemical pathways that generates ammonia in the gut.
Tested in two separate preclinical HE models, the engineered strains delivered striking results. Systemic ammonia was reduced by up to ten-fold. BCAA and L-glutamine levels were restored toward normal ranges. Behavioral assessments showed significant improvements in anxiety-like behavior and cognitive function. Crucially, these effects surpassed those achieved with rifaximin, the leading clinical therapy for HE, while the engineered bacteria also preserved gut microbiota diversity — a major advantage over antibiotic-based approaches.
The broader implication is significant: this work establishes a modular, programmable platform for multi-metabolite intervention. Rather than targeting a single molecule, engineered commensals can be designed to simultaneously correct multiple dysregulated pathways, making them well-suited for complex, multi-factorial disorders.
Caveats include the preclinical nature of the data, with human trials yet to be conducted. The summary is based on the abstract only, so full methodological details, safety data, and long-term colonization outcomes remain unknown.
Key Findings
- Engineered L. plantarum reduced systemic ammonia by up to 10-fold in two preclinical hepatic encephalopathy models.
- One strain converts captured ammonia into branched-chain amino acids, simultaneously fixing two metabolic deficits.
- Engineered bacteria outperformed rifaximin, the current standard-of-care drug for hepatic encephalopathy.
- Treatment restored anxiety-like behavior and cognitive function in animal models.
- Unlike rifaximin, the engineered strains preserved gut microbiota diversity.
Methodology
The study used two preclinical animal models of hepatic encephalopathy to test two separately engineered Lactobacillus plantarum WCFS1 strains. Outcomes included systemic ammonia levels, BCAA and L-glutamine concentrations, gut microbiota diversity, and behavioral measures of anxiety and cognition. Rifaximin was used as an active comparator.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; detailed methods, safety profiles, and long-term data are unavailable. All results are from preclinical animal models, and human efficacy and safety have not yet been established. Regulatory pathways for genetically engineered live biotherapeutics remain complex and uncertain.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.